Immunotherapy boosts chemo against rare sarcomas?
NCT ID NCT03719430
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and worked better than chemo alone. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Columbia University Irving Medical Center/NYP
New York, New York, 10032, United States
-
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110, United States